arrow
L

Luigi Portella

istituto nazionale tumori irccs fondazione g. pascale
H指数:22
被引数:1,652

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CXCR4+ circulating tumor cells (CTCs) accumulate in subcutaneous, immune suppressive, CXCL12-loaded-hydrogel

CXCR4+循环肿瘤细胞(CTCs)在皮下、免疫抑制性、CXCL12负载水凝胶中积累

2026-09-040
OAAI
CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells

CXCR4、CXCR7和PBRM1是人类肾癌细胞中依维莫司和卡博赞尼耐药性的相关因素。

2026-03-280
OAAI
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024-08-211
OAAI
CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization
HELIYON
IF3.6
2024-08-010
OAAI
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients
2024-05-042
OA
CXCL12-loaded-hydrogel (CLG) in vivo modifies lung metastatic niche toward an immunoactive microenvironment reducing lung metastasis development
2024-03-220
PRE
In PD-1+human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies
2022-03-0432
OAAI
Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol

阿柏西普或贝伐单抗联合FOLFIRI作为mRAS转移性结直肠癌患者的二线治疗: 仲裁研究方案

2021-03-2411
OAAI
Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors
2021-03-0412
PREAI
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

靶向CXCR4增强anti-PD-1改善肿瘤微环境和抑制肿瘤PD-1的功效

2019-10-2880
OAAI
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol
2019-09-0911
OAAI